Paul G. Kluetz

9.9k citations
174 papers · 4.0k indexed · 1 hit paper · h-index 34
Topics
Health Systems, Economic Evaluations, Quality of Life (51 papers)Economic and Financial Impacts of Cancer (38 papers)Statistical Methods in Clinical Trials (31 papers)

In The Last Decade

Paul G. Kluetz

157 papers receiving 4.0k citations

Hit Papers

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxet...202220262023202420224080120

Peers

Paul G. Kluetz
Comparison fields: 5 of 118
  • Oncology 1.8k
  • Pulmonary and Respiratory Medicine 1.3k
  • Economics and Econometrics 671
  • Cancer Research 608
  • Molecular Biology 579
Replace Boštjan Šeruga with:
Boštjan Šeruga Canada
Eric X. Chen Canada
Shenghui Tang United States
Francisco Vera-Badillo Canada
Francesco Perrone Italy
Francesco Pignatti Netherlands
Roberta De Angelis Italy
Arnoud J. Templeton Switzerland
Carin A. Uyl‐de Groot Netherlands
Christopher E. Desch United States
Paul G. Kluetz relative to Boštjan Šeruga Canada Boštjan Šeruga's profile →
Citations per field
00.5×1.5×
Boštjan Šeruga · 1×
Citations per year

Countries citing papers authored by Paul G. Kluetz

Since Specialization
Citations

This map shows the geographic impact of Paul G. Kluetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul G. Kluetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul G. Kluetz more than expected).

Fields of papers citing papers by Paul G. Kluetz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul G. Kluetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul G. Kluetz. The network helps show where Paul G. Kluetz may publish in the future.

Co-authorship network of co-authors of Paul G. Kluetz

This figure shows the co-authorship network connecting the top 25 collaborators of Paul G. Kluetz. A scholar is included among the top collaborators of Paul G. Kluetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul G. Kluetz. Paul G. Kluetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 1
4 0
5 5
6 33
7 4
8 0
9 7
10 0
11 16
12 2
13
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancerbreakdown →
127
14 1
15 102
16 44
17 20
18 8
19 240
20 10

About Paul G. Kluetz

Paul G. Kluetz is a scholar working on Statistics and Probability, Oncology and Cancer Research, having authored 174 papers that have together received 4.0k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (51 papers), Economic and Financial Impacts of Cancer (38 papers) and Statistical Methods in Clinical Trials (31 papers). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (608 citations) and Statistics and Probability (321 citations). Paul G. Kluetz has collaborated with scholars based in United States, Netherlands and Canada. Frequent co-authors include Richard Pazdur, Julia A. Beaver, Rajeshwari Sridhara, Ethan Basch, Kirsten B. Goldberg, Gideon M. Blumenthal, Sandra A. Mitchell, Marc R. Theoret, Diana T. Chingos and Laleh Amiri‐Kordestani. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026